At a glance
- Originator Zeria
- Class Antineoplastics; Antiulcers; Benzodiazepines; Benzoic acids; Gastric antisecretories; Urea compounds
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Discontinued Peptic ulcer
Most Recent Events
- 31 Jul 2019 Phase II development is ongoing for Pancreatic cancer (Combination therapy, Metastatic disease) in Japan, South Korea and Taiwan
- 01 Mar 2017 Zeria completes a phase II trial in Pancreatic cancer (Metastatic disease, Combination therapy) in Japan, South Korea & Taiwan (NCT02117258)
- 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in United Kingdom (PO)